SEREVENT DISKUS
LABA DPI
Salmeterol xinafoate · GlaxoSmithKline
Active Medication & Mechanism
- Salmeterol xinafoate LABA50 mcg salmeterol per blister
Long-acting beta2-adrenergic agonist. Provides sustained bronchodilation (≥12 hours) via stimulation of beta2-receptors on airway smooth muscle. Onset is approximately 30–48 minutes.
FDA-Approved Dosing — Strength × Indication
Strength Regimen AsthmaCOPDExercise-Induced Bronchospasm
50 mcg
Varies by indication — see columns
FDA Approved
Adults (≥18 years, only with concomitant ICS) 1 inhalation twice daily (~12 hours apart) → 100 mcg For asthma, the label restricts salmeterol to additional therapy in patients not adequately controlled on an ICS or whose disease warrants ICS + LABA. The label requires concomitant ICS use — salmeterol monotherapy in asthma increases the risk of asthma-related death.
FDA Approved
1 inhalation twice daily (~12 hours apart) → 100 mcg Maintenance treatment of bronchospasm associated with COPD, including emphysema and chronic bronchitis.
FDA Approved
1 inhalation at least 30 minutes before exercise → Should not exceed 1 inhalation twice daily Prevention of exercise-induced bronchospasm. The label states that additional doses are not to be used within 12 hours, and that patients already taking Serevent twice daily are not to use additional doses for EIB.
All regimens shown apply to adults (≥18 years) unless otherwise noted · verify against current labelling
50 mcg
Asthma FDA Approved
Adults (≥18 years, only with concomitant ICS) 1 inhalation twice daily (~12 hours apart) → 100 mcg For asthma, the label restricts salmeterol to additional therapy in patients not adequately controlled on an ICS or whose disease warrants ICS + LABA. The label requires concomitant ICS use — salmeterol monotherapy in asthma increases the risk of asthma-related death.
COPD FDA Approved
1 inhalation twice daily (~12 hours apart) → 100 mcg Maintenance treatment of bronchospasm associated with COPD, including emphysema and chronic bronchitis.
Exercise-Induced Bronchospasm FDA Approved
1 inhalation at least 30 minutes before exercise → Should not exceed 1 inhalation twice daily Prevention of exercise-induced bronchospasm. The label states that additional doses are not to be used within 12 hours, and that patients already taking Serevent twice daily are not to use additional doses for EIB.
All regimens shown apply to adults (≥18 years) unless otherwise noted · verify against current labelling
Not a rescue inhaler. Not for acute bronchospasm. Per labeling, a SABA is used.
Related Inhalers
Other LABA inhalers